



Trial Information Summary

ALLG Trial Number:	ALL06
Trial Name:	
<p>A Phase II trial of an intensive pediatric protocol incorporating post – induction stratification based on Minimal Residual Disease levels for the treatment of adolescents aged 15 years and above, and young adults aged up to 40 years, with newly diagnosed Acute Lymphoblastic Leukaemia (ALL)</p>	
Lay Summary:	
<p>Two thirds of the cases of Acute Lymphoblastic Leukaemia (ALL) occur in children and adolescents. Treatment programs developed in the 1960's and then revised over the past 30 years produce excellent results. Today personalised treatments are achieving cure rates of approximately 80% and with further improvements may reach 90%. However, the results in treatment of adults are poor, with most cure rates less than 40%.</p> <p>There is good evidence that ALL in adults is different to that seen in children. It is unclear if the poor outcomes seen in adult ALL are because of the difference in the disease between the age groups; or if the results of the types of treatment and its delivery, may be important in understanding the outcomes in older patients.</p> <p>This trial will examine whether exactly the treatment given to children can also be given to adults aged 15-40 years, and if so, are the results as good.</p>	
Participating Hospitals:	
<p>1. Alfred / 2. Canberra / 3. Fiona Stanley / 4. Gosford / 5. Liverpool / 6. Prince of Wales / 7. Princess Alexandra / 8. Royal Adelaide / 9. Royal Hobart / 10. Royal North Shore / 11. Royal Prince Alfred / 12. Shoalhaven (Satellite of Woollongong) / 13. Sir Charles Gairdner / 14. Townsville / 15. Westmead / 16. Wollongong</p>	
Target Accrual (International):	N/A
Target Accrual (ALLG):	100 Patients
Expected Final Accrual Date:	July 2016